Клинико-патогенетическая характеристика и факторы прогноза в развитии и течении хронического лимфолейкоза
Диссертация
На основе впервые созданной коллекции ДНК больных хроническим лимфолейкозом проведен молекулярно-генетический анализ генов факторов канцерогенеза N (^01, 1УГОМ2, ВАХ, ТМ^-а и ангиогенеза TEGF, ЬБвР (патент Российской Федерации на изобретение № 2 248 574). На основании результатов проведенных исследований, впервые выявлены генотипы 609*СТ локуса 6090 Т гена канцерогенеза N?>01 (011=0,31- 95% С1… Читать ещё >
Список литературы
- Анализ заболеваемости гемобластозами населения ЗАТО Северск / P.M. Тахауов, А. Б. Карпов, Н. В. Королёва, Л. Ф. Писарева // Здравоохранение Российской Федерации. 2007. — № 1. — С. 24−27.
- Асцатуров, И.А. Иммунофенотипирование в диагностике лимфопролиферативных заболеваний: автореф. дис.. канд. мед. наук. -М., 1997.-20 с.
- Баранова, A.B. Гены-супрессоры опухолевого роста / A.B. Баранова, Н. К. Янковский // Молекулярная биология. 1998. — Т. 32. — С. 206 218.
- Бессмельцев, С.С. Первый опыт применения Веро-Флударабина при хроническом лимфолейкозе и неходжкинских лимфомах / С. С. Бессмельцев, K.M. Абдулкадыров // Онкогематология. 2007. — № 4.
- Бессмельцев, С.С. Практические аспекты применения алемтузумаба (кэмпас) при хроническом лимфолейкозе / С. С. Бессмельцев, Е. В. Карягина, Е. В. Литвинская // Клиническая онкогематология. — 2010. — Т. 3, № 2.
- Бялик, Т.Е. Первый российский опыт лечения хронического лимфолейкоза с аутоиммунными осложнениями антителами против антигена CD52 (кэмпас) / Т. Е. Бялик, О. Л. Тимофеева, М. А. Волкова // Онкогематология. 2007. — № 1. — С. 39−41.
- Бялик, Т.Е. Применение кэмпаса при аутоиммунных осложнениях хронического лимфолейкоза / Т. Е. Бялик // Клиническая онкогематология. 2010. — Т. 3, № 2.
- П.Волкова, М. А. Моноклональные антитела к антигену CD52: оптимизация терапии хронического лимфолейкоза / М. А. Волкова // Гематология и трансфузиология. 2006. — № 2. — С. 27.
- Волкова, М.А. Полвека в терапии хронического лимфолейкоза / М. А. Волкова // Гематология и трансфузиология. 1998. — N4. — С. 6−12.
- И.Волкова, М. А. Ритуксимаб в терапии аутоиммунных осложнений при хроническом лимфолейкозе / М. А. Волкова, Т. Е. Бялик // Гематология и трансфузиология. 2006. — № 3. — С. 11.
- Н.Волкова, М. А. Хронический лимфолейкоз — от рентгенотерапии до кэмпаса / М. А. Волкова // Клиническая онкогематология. 2010. — Т. 3, № 2.-С. 209−210.
- Воробьев, А.И. Лимфоцитома селезенки и классификация лимфоцитом / А. И. Воробьев, М. Д. Бриллиант // Терапевтический архив. 1982. — Т. 54.-С. 8−14.
- Воробьев, А.И. Опухоли лимфатической системы / А. И. Воробьев, Д. В. Кременецкая, Д. В. Харазишвили // Гематология и трансфузиология. -2000.-Т. 43, № 3.-С. 3−14.
- Воробьев, А.И. Хронический лимфолейкоз / А. И. Воробьев, М. Д. Бриллиант // Руководство по гематологии. М.: Медицина, 1985. — С. 273−290.
- Гимаева, З.Ф. Применение циклоферона в комплексном лечении больных хроническим лимфолейкозом на фоне терапии хлорбутином / З. Ф. Гимаева, А. Б. Бакиров // Гематология и трансфузиология. 2005. -№ 5.-С. 11.
- Голенков, А.К. Иммунологический фенотип и клиническое течение неходжкинских лимфом / А. К. Голенков // Гематология и трансфузиология. 1998. — Т. 43, № 1. — С. 41—4.
- Голенков, А.К. Клиническое значение линейно-адгезивного фенотипа лимфопролиферативных заболеваний / А. К. Голенков, А. Ю. Барышников, А. Б. Бакиров. Уфа, 2004. — 178 с.
- Диагностика B-клеточного хронического лимфолейкоза с помощью двуцветной проточной цитофлуориметрии / Ю. Е. Виноградова, И. А. Замулаева, Е. И. Селиванова и др. // Гематология и трансфузиология. -2000.-Т. 45, № 2.-С. 9−12.
- Дифференциальная диагностика периферических мелкоклеточных В-клеточных лимфом / З. В. Тахаев, H.A. Пробатова, H.H. Тупицын и др. // Клиническая геронтология. 2002. — № 1. — С. 15−17.
- Доброкачественная форма XJTJI / Е. И. Яхнина, Е. А. Никитин, И. А. Асцатуров и др. // Терапевтический архив. 1997. — Т. 69. — С. 11−17.
- Домнинский, Д.А. Молекулярные механизмы лейкозогенеза / Д. А. Домнинский // Онкогематология. 2011. — № 3. — С. 82−93.
- Дрейпер, Н. Прикладной регрессионный анализ. Множественная регрессия / Н. Дрейпер, Г. Смит. — 3-е изд. — М.: «Диалектика», 2007. —912 с.
- Елисеева, И.И. Общая теория статистики / И. И. Елисеева, М. М Юзбашев- под ред. И. И. Елисеевой. — 4-е изд., перераб. и доп. — М.: Финансы и Статистика, 2002. — 480 с.
- Животовский, JI.A. Популяционная биометрия / Л. А. Животовский. -М.: Наука, 1991.-272 с.
- Загоскина, Т.П. Эффективность комбинации ритуксимаба, флударабина и циклофосфана при лечении хронического лимфолейкоза / Т. П. Загоскина // Гематология и трансфузиология. -2006.-№ 6.-С. 12.
- Захарова, А.И. Молекулярно-генетические маркеры как факторы прогноза при хроническом B-клеточном лимфолейкозе / А. И. Захарова, Т. Н. Обухова // Онкогематология. 2007. — № 1. — С. 17−23.
- Иммунофенотипирование как способ мониторирования эффективности терапии при хроническом лимфолейкозе / Е. А. Стадник, Е. Е. Зуева, Г. Н. Салогуб и др. // Russian Journal of Immunology. 2004. — Vol. 9, Supp. 1. — P. 304.
- Иммунофенотипическая характеристика морфологических вариантов B-клеточного хронического лимфолейкоза / A.B. Шибинская, М. А. Френкель, H.A. Купрышина, H.H. Тупицын // Вестник РОНЦ им. H.H. Блохина РАМН. 2009. — Т. 20, № 3. — С. 82−91.
- Имянитов, E.H. Применение молекулярно-генетического анализа для выбора противоопухолевой цитостатической терапии / E.H. Имянитов, В. М. Моисеенко // Онкогематология. 2007. — № 3. — С. 4−8.
- Карягин, И.Е. Гетерогенность иммунологического фенотипа и пролиферативных характеристик лимфоидных клеток при В-клеточном хроническом лимфолейкозе / И. Е. Карягин, A.C. Цвейбах, Б. В. Афанасьев // Вопросы онкологии. 1992. — № 6. — С. 667−673.
- Клонирование кандидатного гена Leu5, утрачиваемого у больных В-клеточным XJIJ1, как иллюстрация современной стратегии поиска генов-супрессоров опухолевого роста / А. И. Баранова и др. // Гематология и трансфузиология. 2000. — Т. 45, № 3. — С. 15−19.
- Ковригина, A.M. Лимфома Ходжкина и крупноклеточные лимфомы / A.M. Ковригина, H.A. Пробатова. М.: МИА, 2007. — 212 с.
- Крячок, И.А. Опыт применения алемтузумаба в лечении больных хроническим лимфолейкозом в национальном институте рака Украины / И. А. Крячок // Онкогематология. 2010. — Т. 3, № 2. URL: http://www.clinicaloncology.com.ua/article/2057/onkogematologiya
- Лебедев, К.А. Иммунограмма в клинической практике: Введение в прикл. иммунологию / К. А. Лебедев, И. Д. Понякина. М.: Наука, 1990. — 224 с.
- Лимфоцитома селезенки отдельная нозологическая форма, требующая специфической терапии / Е. И. Яхнина, И. А. Асцатуров, Л.С. Аль-Ради и др. // Терапевтический архив. — 1996. — Т. 68. — С. 4858.
- Луговская, С. А. Клеточные основы классификации лимфопролиферативных заболеваний / С. А. Луговская // Лаборатория. -2001.-№ 2.-С. 3−6
- Маркова, Т.П. Иммунологическая и морфологическая диагностика вариантов хронического лимфолейкоза / Т. П. Маркова, Г. Н. Чувиров // Иммунология. 1990. — № 4. — С. 33−37.
- Мартынкевич, И.С. Цитогенетическая диагностика хронического лимфолейкоза / И. С. Мартынкевич // Клиническая онкогематология. -2010.-Т. 3, № 2.
- Микрочипы в диагностике лимфопролиферативных заболеваний / Т. В. Наседкина, H.A. Гусева, О. Н. Митяева и др. // Молекулярная медицина. 2007. — № 3. — С. 54−60.
- Моисеев, С.И. Современные принципы диагностики и лечения хронического лимфолейкоза / С. И. Моисеев, Е. В. Шляхто. СПб., 2009.
- Молекулярно-биологические факторы прогноза при В-клеточном хроническом лимфолейкозе / Е. А. Никитин, С. Г. Малахов, Б. В. Бидерман и др. // Современная онкология. 2006. — Т. 8, № 1. — С. 3033.
- Морфо-иммунологическая характеристика B-клеточного хронического лимфолейкоза: возрастной аспект / A.B. Шибинская, М. А. Френкель, H.A. Купрышина и др. // Клиническая геронтология. 2009. — Т. 15, № 3. — С. 10−15.
- Нигматуллина, К. И. Заболеваемость, распространенность и выживаемость при хроническом лимфолейкозе в Республике
- Башкортостан за 2001−2005 годы / К. И. Нигматуллина, Д. Х. Калимуллнна, В. Н. Ручкнн // Медицинский вестник Башкортостана. -2007. № 2. — С. 93−98
- Никитин, Е.А. Новый взгляд на лечение хронического лимфоцитарного лейкоза / Е. А. Никитин //Онкогематология. 2010. -№ 3.
- Оценка заболеваемости гемобластозами у персонала радиационно-опасных производств (на примере Сибирского химического комбината) / А. Б. Карпов, P.M. Тахауов, Н. В. Королёва и др. // Сибирский онкологический журнал. 2007. — № 1. — С. 38−43.
- Оценка распространённости гемобластозов среди детского населения г. Северска / Н. В. Королёва, А. Б. Карпов, P.M. Тахауов, Л. Ф. Писарева // Бюллетень сибирской медицины. 2007. — № 2. — С. 103−109.
- Полиморфизм гена р53 как потенциальный маркер предрасположенности к развитию неходжкинских злокачественных лимфом / Т. И. Поспелова, E.H. Воропаева, М. И. Воевода, О. В. Березина // Гематология и трансфузиология. 2010. — № 1. — С. 11.
- Ретроспективное сравнение эффективности и токсичности режимов лечения FC и FCR у первичных больных B-клеточным хроническимлимфолейкозом / Е. А. Стадник, Б. В. Никитин, Г. Н. Бидерман и др. // Онкогематология. 2008. — № 1−2.
- Рукавицын, O.A. Эффективность и безопасность второй линии терапии флударабином с алемтузумабом по сравнению с монотерапией флударабином у больных B-XJIJI / O.A. Рукавицын, В. П. Поп // Клиническая онкогематология. 2010. — Т. 3, № 2.
- Свирновский, А.И. Биологические свойства лейкозных клеток и клинический фенотип при хроническом лимфоцитарном лейкозе / А. И. Свирновский // Гематология и трансфузиология. 2010. — № 1. — С. 25.
- Свирновский, А.И. Хронический лимфоцитарный лейкоз: парадигмы и парадоксы / А. И. Свирновский // Мед. Новости. 2008. — № 13. — С. 7— 19.
- Связь иммунологических и генетических маркеров с ответом на терапию больных В клеточным хроническим лимфолейкозом / Е. А. Стадник, Е. Е. Зуева, Г. Н. Салогуб и др. // Медицинская иммунология. -2004.-Т. 6, № 3−5.-С. 355.
- Смирнова, О.В. Метаболические нарушения в клетках иммунной системы в зависимости от стадии заболевания у больных хроническим лимфолейкозом / О. В. Смирнова, A.A. Савченко, В. Т. Манчук // Медицинская иммунология. 2007. — Т. 9, № 2−3. — С. 288−289.
- Сравнительный анализ данных МТТ-пробы у больных хроническим лимфолейкозом с различным ответом на химиотерапию / Е. В. Катаева, А. К. Голенков, Е. В. Трифонова и др. // Российский биотерапевтический журнал. 2002. — Т. 1, № 1. — С. 65−67.
- Тахауов, P.M. Заболеваемость гемобластозами и лейкозами городского населения г. Северска и персонала Сибирского химического комбината / P.M. Тахауов, А. Б. Карпов, Н. В. Королёва // Радиобиология. Радиоэкология. 2008. — Т. 48, № 3. — С. 326−334.
- Тумаков, В.А. Клинико-морфологические особенности хронического лимфолейкоза / В. А. Тумаков, K.M. Абдулкадыров, В. И. Ругаль // Гематология и трансфузиология. 1998. -№ 3. — С. 32−35.
- Тупицын, H.H. Стандартный иммунологический протокол определения минимальной остаточной болезни при в-клеточном хроническом лимфолейкозе / H.H. Тупицын // Клиническая онкогематология. 2010. -Т.3,№ 2.-С. 217.
- Флударабин в лечении хронического лимфолейкоза / Т. Е. Бялик, Е. Ю. Лысюк, A.A. Молодык и др. // Медико-фармацевтический форум: тезисы докладов. М., 2002. — С. 37−8.
- Флюдарабин в лечении хронического лимфолейкоза / Н. Е. Габеева, A.B. Пивник, Т. Н. Моисеева и др. // Терапевтический архив. 2000. -№ 8. — С. 42−45.
- Хронический B-клеточный лимфолейкоз у лиц моложе 30 лет: агрессивное клиническое течение и рефрактерность к химиотерапии / Е. В. Чигринова, Т. Е. Бялик, Л. Ю. Андреева и др. // Еематология и трансфузиология. 2004. — № 3. — С. 11.
- Цитогенетика хронического B-клеточного лимфолейкоза / А. И. Захарова, Т. Н. Обухова, Ю. Ю. Лорие, Е. В. Домрачева // Медицинская генетика. 2006. — № 3 (45). — С. 27−32.
- Цитогенетические нарушения при хроническом В-клеточном лимфолейкозе и их связь с клинико-биологическими особенностями и прогнозом заболевания / А. И. Захарова, Т. Н. Обухова, Ю. Ю. Лорие и др. // Терапевтический архив. 2006. — № 7. — С. 57−62.
- П.М. Чумаков // Биохимия. 2000. — Т. 65. — С. 34−47. 90. Эконометрия / В. И. Суслов, Н. М. Ибрагимов, Л. П. Талышева,
- A casecontrol study of leukemia in the U.S. rubber industry / P.H. Wolf, D. Andjelkovich, A. Smith, H. Tyroler // J. Occup. Med. 1981. — Vol. 23. — P. 103−108.
- A clinical evaluation of the International Lymphoma Study Group classification of Non-Hodgkin's Lymphoma // Blood. 1997. — Vol. 89. — P. 3909−3918.
- A comparison of genetic and environmental variance structures for asthma, hay fever and eczema with symptoms of the same diseases: a study of Norwegian twins / W. Nystad, E. Roysamb, P. Magnus et al. // Int. J. Epidemiol.-2005.-Vol. 34.-P. 1302−1309.
- A lack of a functional NAD (P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions / J.L. Wiemels, A. Pagnamenta, G.M. Taylor et al. // Cancer Res. 1999. — Vol. 59. — P. 4095−9.
- A prospective study of permanent hair dye use and hematopoietic cancer / F. Grodstein, C.H. Hennekens, G.A. Colditz et al. // J. Nat. Cancer Inst. -1994.-Vol. 86.-P. 1466−1470.
- A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans / G.L. Bond, W. Hu, E.E. Bond et al. // Cell. 2004. — Vol. 119. — P. 591 602.
- A single round PCR method for genotyping human surfactant protein (SP)-Al, SP-A2 and SP-D gene alleles / P. Pantelidis, A.L. Lagan, J.C. Davies Tet al. // Tissue Antigens. 2003. — Vol. 61, № 4. — P. 317−321.
- Acquired immune related and inflammatory conditions and subsequent chronic lympocytic leukemia / O. Landgren, J.S. Rapkin, D. Check et al. // Br. J. Haematol. 2007. — Vol. 139. — P. 791−798.
- Adams, J.M. Life-or-death decisions by the Bcl-2 protein family / J.M. Adams, S. Cory // Trends Biochem Sci. 2001- 26:61−66.
- All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells / O. Bairey, O. Boycov, E. Kaganovsky et al. // Leuk. Res. 2004. — Vol. 28. — P. 243 248.
- Allelic heterogeneity in hereditary surfactant protein B deficiency / L.M. Nogee, S.E. Wert, S.A. Proffit et al. // Am. J. Respir. Crit. Care Med. -2000.-Vol. 161.-P. 973−981.
- Altekruse, S.F. Deaths from hematopoietic and other cancers in relation to permanent hair dye use in a large prospective study (United
- States) / S.F. Altekruse, S.J. Henley, M.J. Thun // Cancer Caus. Control. -1999.-№ 10.-P. 617−625.
- An additional breakpoint in the BCL-1 locus associated with the t (lI-14)(ql3-q32) translocation of B-lymphocytic malignancy / T.C. Meeker, J.C. Grimaldi, R. O’Rourke et al. // Blood. 1989. — Vol. 74. — P. 1801−1806.
- An association between NQOlgenetic polymorphism and risk of bladder cancer / S.-J. Park, H. Zhao, M.R. Spitz et al. // Mutat. Res. -2003.-Vol. 536.-P. 131−7.
- Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia / K.J. Tracey, Y. Fong, D.G. Hesse et al. // Nature. -1987. Vol. 330. — P. 662−664.
- Antigenic stimulation and the occurrence of chronic lymphocytic leukemia / K.A. Rosenblatt, T.D. Koepsell, J.R. Daling et al. // Am. J. Epidemiol. 1991. — Vol. 134. — P. 22−28.
- Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia / C. Pepper, A. Thomas, T. Hoy et al. // Br. J. Haematol. 1999. — Vol. 107. — P. 611−615.
- Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964−2003 / I. Turesson, M.S. Linet, M. Bjorkholm et al. // Int. J. Cancer. 2007. -doi:10.1002/ijc.22 912.
- Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer / H. Lind, S. Zienolddiny, P.O. Ekstrom et al. // Int. J. Cancer. 2006. — Vol. 119. — P. 718−721.
- Association ofNQOl polymorphism with spontaneous breast cancer in two independent populations / H.-J. Menze, J. Sarmanova, P. Soucek et al. // Br. J. Cancer. 2004. — Vol. 90. — P. 1989−94.
- Austin, H. Cigarette smoking and leukemia / H. Austin, P. Cole // J. Chronic Dis. 1986. — Vol. 39. — P. 417—421.
- Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration / S. Dias, K. Hattori, Z. Zhu et al. // J. Clin. Invest. -2000.-Vol. 106.-P. 511−521.
- Automated genomic profiling in chronic lymphocytic leukemia using microarray-based hybridization (Matrix-CGH) / C. Schwanen, M. Nessling, S. Wessendorf et al. // Blood. 2001. — Vol. 98, Suppl. 1. — Abstr. 3178.
- Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis / A. Konig, T. Menzel, S. Lynen et al. // Leukemia. 1997. — № 11.-P. 258−265.
- Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome / L.E. Robertson, W. Plunkett, K. McConnell et al. // Leukemia. 1996. — № 10. — P. 456−459.
- BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism / A. Majid, O. Tsoulakis, R. Walewska et al. // Blood. -2008. Vol. 111, № 2. — P. 874−7.
- Bcl-2 maintains B cell memory / G. Nunez, D. Hockenbery, T.J. McDonnell et al. // Nature. 1991. — № 353 (6339). — P. 71 -73.
- BCL2−938C>A polymorphism and disease progression in chronic lymphocytic leukemia / T. Zenz, A. Benner, U. Duhrsen et al. // Leuk. Lymphoma. 2009. — Vol. 50, № 11. — P. 1837−42.
- B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules / N.E. Kay, N.D. Bone, R.C. Tschumper et al. // Leukemia. 2002a. — Vol. 16. — P. 911 -919.
- Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling / G. Roue, M. Lopez-Guerra, P. Milpied et al. // Clin. Cancer Res. 2008. -№ 14 (21). -P. 6907−15.
- Blair, A. Leukemia cell types and agricultural practices in Nebraska / A. Blair, D.W. White // Arch. Environm. Health. 1985. — Vol. 40. — P. 211−214.
- Blood transfusion and non-Hodgkin lymphoma: lack of association / J. Adami, O. Nyren, R. Bergstrom et al. // Ann. Int. Med. 1997. — Vol. 127. -P. 365−371.
- Blood transfusions and risk of non- Hodgkin’s lymphoma subtypes and chronic lymphocytic leukemia / J.R. Cerhan, R.B. Wallace, F. Dick et al. // Cancer Epidemiol. Biomark. Prevent. 2001. — № 10. — P. 361−368.
- Body mass index and risk of leukemia in older women / J.A. Ross, E. Parker, C.K. Blair et al. // Cancer Epidemiol. Biomark. Prevent. 2004. -Vol. 13.-P. 1810−1813.
- Body mass index and risk of malignant lymphoma in Scandinavian men and women / E.T. Chang, H. Hjalgrim, K.E. Smedby et al. // J. Nat. Cancer Inst. 2005. — Vol. 97. — P. 210−218.
- Brenner, H. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level / H. Brenner, A. Gondos, D. Pulte // Haematologica.- 2008. Vol. 93. — P. 1544−1549.
- Brick mortar exposure and chronic lymphocytic leukemia / L. Markovic-Denic, S. Jankovic, J. Marinkovic, Z. Radovanovic // Neoplasma.- 1995.-Vol. 42.-P. 79−81.
- Burmeister, L.F. Leukemia and farm practices in Iowa / L.F. Burmeister, S.F. Van Lier, P. Isacson // Am. J. Epidemiol. 1982. — Vol. 115.-P. 720−728.
- Caligaris-Cappio, F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells / F. Caligaris-Cappio // Blood. 1996. — Vol. 87. — P. 2615−2620.
- Campath-IH in refractory B-CLL complete remission despite p53 gene mutation / S. Stilgenbauer, K. Scherer, A. Krober et al. // Blood. -2001. — Vol. 98, Suppl. 1. — Abstr. 3211.
- Can older cancer patients tolerate chemotherapy? A prospective pilot study / H. Chen, A. Cantor, J. Meyer et al. // Cancer. 2003. — Vol. 97, № 4.-P. 1107−14.
- Cancer mortality after iodine-131 therapy for hyperthyroidism / P. Hall, G. Berg, G. Bjelkengren et al. // Int. J. Cancer. 1992. — Vol. 50. — P. 886−890.
- Cancer mortality risk among workers at the Mayak nuclear complex / N.S. Shilnikova, D.L. Preston, E. Ron et al. // Radiat. Res. 2003. — Vol. 159.-P. 787−798.
- Cancer risk in the rubber industry: a review of the recent epidemiological evidence / M. Kogevinas, M. Sala, P. Boffetta et al. // Occup. Environm. Med. 1998. — Vol. 55. — P. 1−12.
- Cancer Statistics 2010 / A. Jemal, R. Siegel, J. Xu, E. Ward // Cancer J. Clin. 2010. — Vol. 60. — P. 277−300.
- CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment / P.E.M. Patten, A.G.S. Buggins, J. Richards et al.//Blood.-2008.-Vol. 111,№ 10.-P. 5173—5181.
- Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia / A. Aguayo, E. Estey, H. Kantarjian et al. // Blood. 1999. — Vol. 94. — P. 3717−3721.
- Characterization of a polymorphism in NAD (P)H: quinine oxidoreductase (DT-diaphorase) / R.D. Traver, D. Siegel, H.D. Beall et al. // Br. J. Cancer. 1997. — Vol. 75. — P. 69−75.
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas / J.L. Teeling, R.R. French, M.S. Cragg et al. // Blood. 2004. — Vol. 104. — P. 17 931 800.
- Chemical exposures and risk of chronic lymphocytic leukemia / A. Blair, M.P. Purdue, D.D. Weisenburger, D. Baris // Br. J. Haematol. 2007. -Vol. 139.-P. 753−761.
- Chromosome abnormalities in B cell chronic lymphocytic leukemia and their clinical correlations / M.L. Bird, Y. Ueshima, J.D. Rowley et al. //Leukemia. 1989.-№ 3.-P. 182−191.
- Chromosome abnormalities involving band 13ql4 in hematologic malignancies / M. Fitchett, M.J. Griffiths, D.G. Oscier et al. // Cancer Genet. Cytogenet.- 1987.-Vol. 24.-P. 143−150.
- Chronic lymphocytic leukaemia and radiation: findings among workers at five US nuclear facilities and a review of the recent literature / M.K. Schubauer-Berigan, R.D. Daniels, D.A. Fleming et al. // Br. J. Haematol. 2007. — Vol. 139. — P. 799−808.
- Chronic lymphocytic leukaemia in twin sisters: monozygous but not identical / F. Brok-Simoni, G. Rechavi, N. Katzir, I. Ben-Bassat // Lancet. -1987. № 1.-P. 329−330.
- Chronic lymphocytic leukemia and acquired disorders affecting the immune system: a case-control study /M.S. Linet, L.D. McCaffrey, R.L. Humphrey et al. // J. Nat. Cancer Inst. 1986. — Vol. 77. — P. 371−378.
- Chronic lymphocytic leukemia and small lymphocytic lymphoma: overview of the descriptive epidemiology / G.M. Dores, W.F. Anderson, R.E. Curtis et al. // Br. J. Haematol. 2007. — Vol. 139. — P. 809−819.
- Chronic lymphocytic leukemia in Hiroshima and Nagasaki, Japan / S.C. Finch, T. Hoshino, T. Itoga et al. // Blood. 1969. — Vol. 33. — P. 7986.
- Chronic lymphocytic leukemia in the young patient / M. de Lima, S. O’Brien, S. Lerner, M.J. Keating // Semin. Oncol. 1998. — Vol. 25, № 1. -P. 107−16.
- Cigarette smoking and leukemia: results from the Lutheran Brotherhood Cohort Study / M.S. Linet, J.K. McLaughlin, A.W. Hsing et al. //Cancer Caus. Control. 1991.-№ 2.-P. 413117.
- Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia / J. Gora-Tybor, J.Z. Blonski, T. Robak // Eur. Cytokine Netw. 2005. — Vol. 16. — P. 41−46.
- Classification of lymphoid neoplasms: the microscope as a tool for disease discovery / E.S. Jaffe, N.L. Harris, H. Stein, P.G. Isaacson // Blood. 2008. — Vol. 112. — P. 4384−4399.
- Clinical and morphologic features of B-cell small lymphocytic lymphoma with del (6)(q21q23) / K. Offit, D.C. Louie, N.Z. Parsa et al. // Blood. 1994.-Vol. 83.-P. 2611−2618.
- Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia / A. Aguayo, S. O’Brien, M. Keating et al. // Blood. 2000. — Vol. 96. — P. 768−770.
- Clonal evolution in B-CLL: acquisition of deletions involving 6q21, 1 lq22 and 17pl3 (TP53) associated with disease progression / E. Leupolt, S. Stilgenbauer, A. Kro"ber et al. // Blood. 2001. — Vol. 98, Suppl. 1. -Abstr. 1968.
- Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t (ll-14) chromosome translocation / Y. Tsujimoto, E. Jaffe, J. Cossman et al. // Nature. 1985. — Vol. 315. — P. 343−345.
- Co morbidity and functional status are independent in older cancer patients / M. Extermann, J. Overcash, G.H. Lyman et al. // J. Clin. Oncol. -1998.-Vol. 16, № 4.-P. 1582−7.
- Cockcroft, D.W. Prediction of creatinine clearance from serum creatinine / D.W. Cockcroft, M.H. Gault // Nephron. 1976. — Vol. 16. — P. 31−41.
- Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia / A. Sawitsky, K.R. Rai, O. Glidewell, R.T. Silver // Blood. 1977. — Vol. 50. -P. 1049−1059.
- Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocyticleukaemia cells / G. Dewson, R.T. Snowden, J.B. Almond et al. // Oncogene. 2003. — Vol. 22. — P. 2643−2654.
- Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia / D.G. Oscier, J. Stevens, T.J. Hamblin et al. // Br. J. Haematol. 1990. — Vol. 76. — P. 352−358.
- Court-Brown, W. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis / W. Court-Brown, R. Doll // Br. Med. J. 1965. -№ 2. — P. 1327−1332.
- Cytogenetic studies in chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia: a progress report / T. Han, N. Sadamori, A.M.W. Block et al. // Nouv. Rev. Fr. Hematol. 1988. — Vol. 30. — P. 393−395.
- Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County / R.P. Gale, W. Cozen, M.T. Goodman et al. // Leuk. Res. 2000. — Vol. 24. — P. 665−669.
- Delayed complete response after allogeneic bone marrow transplantation in chronic lymphocytic leukemia / I. Jarque, J. Palau, G.F. Sanz et al. // Blood. 1993. -Vol. 82.-P. 1036−1038.
- Deletions at llq identify a subset of patients with typical CLL who show consistent disease progression and reduced survival / J.R. Neilson, R. Auer, D. White et al. // Leukemia. 1997. — № 11. — P. 1929−1932.
- Developmentally restricted immunoglobulin heavy-chain variable region gene expressed at high frequency in chronic lymphocytic leukemia / T.J. Kipps et al. // Proc. Natl. Acad. Sei. 1989. — Vol. 86. — P. 59 135 917.
- Dighiero, G. Chronic lymphocytic leukemia treatment / G. Dighiero // Hematol. Cell Ther. 1997. — Vol. 39, Suppl. 1. — P. S31-S40.
- Dinucleotide repeats in the human surfactant protein-B gene and respiratory-distress syndrome / J. Floros, S.V. Veletza, P. Kotikalapudi et al. // Biochem. J. 1995. — Vol. 305. — P. 583−590.
- Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA / M. Andreef, Z. Darzynkiewicz, T.K. Sharpless et al. // Blood. 1980. — Vol. 55. — P. 282.
- Distribution and impact of co morbidity in chronic lymphocytic leukemia: meta-analysis of two phase III trials of the German CLL Study Group (GCLLSG) / V. Goede, P. Cramer, R. Busch et al. // Leuk. Lymphoma. 2005. — Vol. 46. — P. 105.
- Doney, K. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia / K. Doney, T. Chauncey, F. Appelbaum // Bone Marrow Transplant. 2002. — Vol. 29. -P. 817−823.
- Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia / M.J. Keating, S. O’Brien, M. Albitar et al. // J. Clin. Oncol. -2005. Vol. 23. — P. 4079−4088.
- Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates / D.L. Preston, D.A. Pierce, Y. Shimizu et al. // Radiat. Res. 2004. — Vol. 162. — P. 377−389.
- Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries / E. Cardis et al. // Radiat. Res. 1995. — Vol. 142. — P. 117−132.
- Efficacy of lenalidomide in myelodysplasia syndromes / A. List, S. Kurtin, D.J. Roe et al. // N. Engl. J. Med. 2005. — Vol. 352. — P. 549 557.
- Eichhorst, B. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL) / B. Eichhorst, M. Hallek // Best Pract. Res. Clin. Haematol. 2007. — Vol. 20. — P. 469−477.
- Elevated intracellular level of basic fibroblast factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine / T. Menzel, Z. Rahman, E. Calleja et al. // Blood. 1996. -Vol. 87.-P. 1056−1063.
- Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progression in early, non-smoldering chronic lymphocytic leukemia / M. Hallek, I. Langenmayer, C. Nerl et al. // Blood. 1999. -Vol. 93.-P. 1732−1737.
- Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis / M.J. Jarzynka, P. Guo, I. Bar-Joseph et al. // Int. J. Oncol. 2006. — Vol. 28.-P. 337−344.
- Ethnic variation in the prevalence of a common NAD (P)H quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy / K.T. Kelsey, D. Ross, R.D. Traver et al. // Br. J. Cancer. -1997.-Vol. 76.-P. 852−4.
- Evaluation of Oncologic Risk under Ionizing Radiation Influence / R.M. Takhauov, Yu.V. Semenova, Zh.O. Vostrova et al. // The second Asian and Oceanic Congress for Radiation Protection. China, 2006. — P. 343−344.
- Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies / L. Borche, A. Lim, J.L. Binet, G. Dighiero // Blood. 1990. — Vol. 76. — P. 562−569.
- Exploiting gene-environment interaction to detect genetic associations / P. Kraft, Y.C. Yen, D.O. Stram et al. // Human Heredity. 2007. — Vol. 63.-P. 111−119.
- Expression of the bcl-2 oncogene protein is not specific for the 14−18 chromosomal translocation / F. Pezella, A.G.D. Tse, J.L. Cordell et al. // Am. J. Pathol. 1990.-Vol. 137.-P. 225.
- Expression of ZAP-70 is associated with increased B-cell receptor signalingin chronic lymphocytic leukemia / L. Chen, G. Widhopf, L. Huynh et al. // Blood. 2002. — Vol. 100. — P. 4609−4614.
- Extermann, M. Measurement and impact of co morbidity in older cancer patients / M. Extermann // Crit. Rev. Oncol. Hematol. 2000. — Vol. 35, № 3.-P. 181−200.
- Familial cancer history and chronic lymphocytic leukemia. A case-control study / M.S. Linet, M.L. Van Natta, R. Brookmeyer et al. // Am. J. Epidemiol.-1989.-Vol. 130.-P. 655−664.
- Familial leukaemia: a study of 909 families / F.W. Gunz, J.P. Gunz,
- A.M. Veale et al.//Scand. J. Haematol. 1975. — Vol. 15. — P. 117−131.
- Familial risk and cancer control / H.T. Lynch, F.D. Brodkey, P. Lynch et al. // J. Am. Assoc. 1976. — Vol. 236. — P. 582−584.
- Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish family-cancer database / L.R. Goldin, R.M. Pfeiffer, X. Li, K. Hemminki // Blood. 2004. -Vol. 104.-P. 1850−1854.
- Feychting, M. Occupational and residential magnetic field exposure and leukemia and central nervous system tumors / M. Feychting, U. Forssen,
- B. Floderus // Epidemiology. 1997. — № 8. — P. 384−389.
- Floderus, B. Incidence of selected cancers in Swedish railway workers, 1961−79 / B. Floderus, S. Tornqvist, C. Stenlund // Cancer Caus. Control.- 1994.-№ 5.-P. 189−194.
- Fluorescence in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia / S.M. Escudier et al. // Blood. 1993. -Vol. 81.-P. 2702−2707.
- Four aged siblings with B cell chronic lymphocytic leukemia / F. Fernhout, R.B. Dinkelaar, A. Hagemeijer et al. // Leukemia. 1997. — № 11.-P. 2060−2065.
- Fraumeni Jr., J.F. Familial chronic lymphocytic leukemia / J.F. Fraumeni Jr., C.L. Vogel, V.T. DeVita // Ann. Int. Med. 1969. — Vol. 71. -P. 279−284.
- Friedman, G.D. Cigarette smoking, leukemia, and multiple myeloma /
- G.D. Friedman // Ann. Epidemiol. 1993. — № 3. — P. 425−428.
- Garfinkel, L. Association between smoking and leukemia in two American Cancer Society prospective studies / L. Garfinkel, P. Boffetta // Cancer. 1990. — Vol. 65. — P. 2356−2360.
- Gene-expression profiling of B-cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells / U. Klein et al.//J. Exp. Med.-2001.-Vol. 194.-P. 1625−1638.
- Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course / S. Stilgenbauer, L. Bullinger, P, Lichter, H. Dohner // Leukemia. 2002. -Vol. 16.-P. 993−1007
- Genomic aberrations and survival in chronic lymphocytic leukemia /
- H. Dohner, S. Stilgenbauer, A. Benner et al. // N. Engl. J. Med. 2000. -Vol. 343.-P. 1910−1916.
- Gunz, F.W. Chronic lymphocytic leukemia in a family, including twin brothers and a son / F.W. Gunz, W. Dameshek // J. Am. Assoc. 1957. -Vol. 164.-P. 1323−1325.
- Hair dye use and risk of fatal cancers in U.S. women / M.J. Thun, S.F. Altekruse, M.M. Namboodiri et al. // J. Nat. Cancer Instit. 1994. — Vol. 86.-P. 210−215.
- Hall, P. Cancer in iodine-131 exposed patients / P. Hall, L.E. Holm // J. Endocrinol. Investig. 1995. — Vol. 18. — P. 147−149.
- Hallek, M. Chronic Lymphocytic Leukemia (CLL): First-Line Treatment / M. Hallek // Hematology. Berlin, 2005. — P. 285−291.
- Havill, L.M. Association mapping: methodologies, strategies, and issues / L.M. Havill, T.D. Dyer // Gen. Epidemiol. 2005. — Vol. 29, Suppl. l.-P. S77-S85.
- Hemann, M.T. The p53-Bcl-2 connection / M.T. Hemann, S.W. Lowe // Cell Death Differentiat. 2006. — Vol. 13. — P. 1256−1259.
- Heterogeneous proliferative effect of tumor necrosis factor-alpha and lymphotoxin on mitogenactivated B cells from B-chronic lymphocytic leukemia / M. Alvarez-Mon, J. Garcia-Suarez, A. Prieto et al. // Am. J. Hematol.- 1993.-Vol. 43.-P. 81−85.
- High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia / A. Ferrajoli, T. Manshouri, Z. Estrov et al. // Clin. Cancer Res. 2001. — № 7. — P. 795 799.
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma / P.G. Richardson,
- R.L. Schlossman, E. Weller et al. // Blood. 2002. — Vol. 100. — P. 30 633 067.
- Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b) / E.J. Moreau, E. Matutes, R.P. A’Hern et al. // Am. J. Clin. Pathol. 1997. — Vol. 108. — P. 378−382.
- Incidence and corralation of genomic aberrations with clinical and biological risk factors in B-CLL stage Binet-A within the CLL1 trial of the GCLLSG / L. Bullinger, C. Krutle, R. Busch et al. // Blood. 2001. — Vol. 98, Suppl. 1.- Abstr. 1512.
- Incidence of leukemia in Asian migrants to the United States and their descendants / J.W. Pan, L.S. Cook, S.M. Schwartz, N.S. Weis // Cancer Caus. Control. 2002. — Vol. 13.-P. 791−795.
- Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners: a case-cohort study / V. Rericha, M. Kulich, R. Rericha et al. // Environm. Health Perspect. 2006. — Vol. 114. — P. 818−822.
- Increased frequency of a null-allele for NAD (P)H: quinine oxidoreductase in patients with urological malignancies / W.A. Schulz, A. Krummeck, I. Rosinger et al. // Pharmacogenetics. 1997. — № 7. — P. 235−9.
- Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia / S.
- Molica, G. Vitelli, D. Levato et al. // Br. J. Haematol. 1999. — Vol. 107. -P. 605−610.
- Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer / H. Kuniyasu, W. Yasui, H. Shinohara et al. // Am. J. Pathol. -2000.-Vol. 157.-P. 1523−1535.
- Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2 / H. Zhang, Y. Li, H. Li et al. // Leuk. Lymphoma. -2004.-Vol. 45.-P. 1887−1897.
- Investigation of an NQOl polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia / A. Begleiter, D. Hewitt, S.B. Gibson, J.B. Johnston // Leuk. Res. 2009. — Vol. 33. — P. 7481.
- Ionizing radiation and chronic lymphocytic leukemia / D.B. Richardson, S. Wing, J. Schroeder et al. // Environ. Health Perspect. -2005.-Vol. 113.-P. 1−5.
- Jaiswal, A.K. Human NAD (P)H:quinone oxidoreductase (NQO-1) gene structure and induction by dioxin / A.K. Jaiswal // Biochemistry. -1991.-Vol. 30.-P. 10 647−53.
- Juliusson, G. Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 662 patients / G. Juliusson, D. Oscier, G. Gahrton // Leuk. Lymphoma. 1991. — № 5. -P. 21−25.
- Kaplan, E.I. Nonparametric estimation from incomplete observations / E.I. Kaplan, P. Meier // J. Am. Stat. Assoc. 1958. — Vol. 53. — P. 457.
- Karyotypic evolution in B-cell chronic lymphocytic leukemia / D. Oscier, M. Fitchett, T. Herbert, R. Labert // Genes. Chromos. Cancer. -1991. -№ 3.-P. 16−20
- Karyotypic evolution in CLL. Identification of a new sub-group of patients with deletions of llq and advanced or progressive disease / C.
- Fegan, H. Robinson, P. Thompson et al. // Leukemia. 1995. — № 9. — P. 2003−2008.
- Keller, B.K. Predictors of mortality in outpatient geriatric evaluation and management clinic patients / B.K. Keller, J.F. Potter // J. Gerontol. -1994. Vol. 49, № 6. — P. M246−51.
- Kini, A.R. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia / A.R. Kini, N.E. Kay, L.C. Peterson // Leukemia. -2000.-Vol. 14.-P. 1414−1418.
- Kinlen, L.J. Leukaemia and smoking habits among United States veterans / L.J. Kinlen, E. Rogot // Br. Med. J. 1988. — Vol. 297. — P. 657 659.
- Kraft, P. Case-sibling gene-association studies for diseases with variable age at onset / P. Kraft, D.C. Thomas // Stat. Med. 2004. — Vol. 23. -P. 3697−3712.
- Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia / K. Bogunia-Kubik, G. Mazur, I. Urbanowicz et al. // Int. J. Immunogenet. -2006.-Vol. 33, № 1.-P. 21−4.
- Late effects in ankylosing spondylitis patients treated with 224Ra / R.R. Wick, E.A. Nekolla, W. Gossner, A.M. Kellerer // Radiat. Res. 1999. -Vol. 152.-P. S8-S11.
- Lessons from phase III clinical trials on anti-VEGF therapy for cancer / R.K. Jain, D.G. Duda, J.W. Clark, J.S. Loeffler // Nat. Clin. Pract. Oncol. -2006.-№ 3.-P. 24−40.
- Leukemia following radiotherapy for uterine bleeding / P.D. Inskip, R.R. Monson, J.K. Wagoner et al. // Radiat. Res. 1990. — Vol. 122. — P. 107−119.
- Leukemia in atomic bomb survivors: Hiroshima and Nagasaki TR-25−69. Atomic Bomb Casualty Commission / T. Ischimaru, T. Hoshino, M. Ichimaru et al. Hiroshima, Japan, 1969.
- Leukemia mortality after X-ray treatment for ankylosing spondylitis / H.A. Weiss, S.C. Darby, T. Fearn, R. Doll // Radiat. Res. 1995. — Vol. 142.-P. 1−11.
- Leukemia risk associated with low-level benzene exposure / D.C. Glass, C.N. Gray, D.J. Jolley et al. // Epidemiology. 2003. — Vol. 14. — P. 569−577.
- Leukemia risk following radiotherapy for breast cancer / R.E. Curtis, J.D. Boice Jr., M. Stovall et al. // J. Clin. Oncol. 1989. — № 7. — P. 2129.
- Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease / P.D. Inskip, R.A. Kleinerman, M. Stovall et al. // Rad. Res. 1993.-Vol. 135.-P. 108−124.
- Leukemia, lymphoma, and multiple myeloma following selected medical conditions / M.M. Doody, M.S. Linet, A.G. Glass et al. // Cancer Caus. Control. 1992. — № 3. — P. 449−456.
- Levels of expression of CD 19 and CD20 in chronic B cell leukaemias / L. Ginaldi, M. De Martinis, E. Matutes et al. // J. Clin. Pathol. 1998. -Vol. 51.-P. 364−369.
- Levine, A.J. The p53 tumour suppressor gene / A.J. Levine, J. Momand, C.A. Finlay //Nature. 1991. -№ 351 (6326). — P. 453−6.
- Linet, M. The leukemias / M. Linet, S.S. Devesa, G.J. Morgan // Cancer Epidemiology and Prevention / ed. by D. Schottenfeld, J.F. Fraumeni Jr.). Oxford University Press Inc., New York, 2006. — P. 841— 871.
- Linn, B.S. Cumulative illness rating scale / B.S. Linn, M.W. Linn, L. Gurel // J. Am. Geriatr. Soc. 1968. — Vol. 16, № 5. — P. 622−6.
- Low NAD (P)H: quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults / M.T. Smith, Y. Wang, E. Kane et al. // Blood. 2001. — Vol. 97. — P. 1422−6.
- Making YAC and cosmid contig spanning 13ql4.3 region frequently lost in chronic lymphocytic leukemia / V.M. Brodjansky, G.E. Sulimova, I.G. Udina et al. // Abstr. of the 3d Human chromosome 13 workshop. -Tarry to wn, NJ USA, 1995.
- Mathew, C.C. The isolation of high molecular weight eukaryotic DNA / C.C. Mathew // Methods in Molecular Biology / ed. J.M. Walker. N.Y., L.: Human Press, 1984. — Vol. 2. — P. 31−34.
- McBride, O.W. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17pl3) / O.W. McBride, D. Merry, D. Givol // Proc. Natl. Acad. Sci. 1986.-Vol. 83, № l.-P. 130−134.
- MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis / N. Ohmiya, A. Taguchi, N. Mabuchi et al. // J. Clin. Oncol. 2006. — Vol. 24. — P. 44 344 440.
- MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner / G.L. Bond, K.M. Hirshfield, T. Kirchhoff et al. // Cancer Res. 2006. — Vol. 66. — P. 5104−5110.
- MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia /1. Gryshchenko, S. Hofbauer, M. Stoecher et al. // J. Clin. Oncol. 2008. — Vol. 26, № 14. — P. 141−142.
- Measuring co morbidity in patients with head and neck cancer / S.F. Hall, P.A. Rochon, D.L. Streiner et al. // Laryngoscope. 2002. — Vol. 112, № 11.-P. 1988−96.
- Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines / N.I. Pathan, P. Chu, K. Hariharan et al. // Blood. 2008. — Vol. 111. — P. 1 594 602.
- Michael, D. The p53-Mdm2 module and the ubiquitin system / D. Michael, M. Oren // Semin. Cancer Biol. 2003. — Vol. 13. — P. 49−58.
- Misra, V. Transfection of COS-1 cells with DT diaphorase cDNA: role of a base change at position 609 / V. Misra, H.J. Klamut, A.M. Rauth // Br. J. Cancer. 1998. — Vol. 77. — P. 1236−40.
- Mitsiades, C.S. CC-5013 (Celgene) / C.S. Mitsiades, N. Mitsiades // Curr. Opin. Investig. Drugs. 2004. — № 5. — P. 635−647.
- Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t (l 1−14) chromosome translocation / Y. Tsujimoto, J. Yunis, L. Onorato-Showe et al. // Science. 1984. — Vol. 224.-P. 1403−1406.
- Molecular cytogenetic analysis of Rb-1 deletions in chronic B-cell leukemias / H. Dohner, T. Pilz, K. Fischer et al. // Leuk. Lymphoma. — 1994.-Vol. 16.-P. 97−103.
- Moll, U.M. p53—an acrobat in tumorigenesis / U.M. Moll, L.M. Schramm // Crit. Rev. Oral Biol. Med. 1998. — Vol. 9, № 1. — P. 23−37.
- Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia (CLL) / A.C. Rawstron, F.L. Bennett, S.J. O’Connor et al. // N. Engl. J. Med. 2008. — Vol. 359. — P. 575−583.
- Montserrat, E. Chronic lymphocytic leukemia: Prognostic factors and natural history / E. Montserrat, C. Rozman // Baillieres Clin. Haematol. -1993.-№ 6.-P. 849.
- Morley, R. Studies of twins: what can they tell us about the fetal origins of adult disease? / R. Morley, T. Dwyer // Paediatr. Perinat. Epidemiol.-2005.-Vol. 19, Suppl. l.-P. 2−7.
- Mortality among radiation workers at Rocketdyne (Atomics International), 1948−1999 / J.D. Boice, S.S. Cohen, M.T. Mumma et al. // Radiat. Res. 2006. — Vol. 166. — P. 98−115.
- Mortality from cancer and other causes among airline cabin attendants in Germany, 1960−1997 / M. Blettner, I-I. Zeeb, I. Langner et al. // Am. J. Epidemiol. 2002. — Vol. 156. — P. 556−565.
- Mortality in a cohort of women given X-ray therapy for metropathia haemorrhagica / S.C. Darby, G. Reeves, T. Key et al. // Int. J. Cancer. -1994. Vol. 56. — P. 793−801.
- Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy / I. Sturm, A.G. Bosanquet, S. Hermann et al. // Cell Death Differ. 2003. — № 10. -P. 477−484.
- Myeloma and the t (l I-14)(ql3-q32) — evidence for a biologically defined unique subset of patients / R. Fonseca et al. // Blood. 2002. -Vol. 99.-P. 3735−3741
- NAD (P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations / A. Gaedigk, R.F. Tyndale, M. Jurima-Romet et al. // Pharmacogenetics. 1998. -№ 8. — P. 305−13.
- NAD (P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors / M.J. Lafuente, X. Casterad, M. Trias et al. // Carcinogenesis. 2000. -Vol.21.-P. 1813
- Nathan, C.F. Secretory products of macrophages / C.F. Nathan // J. Clin. Invest. 1987. — Vol. 79. — P. 319−326.
- National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment / B.D. Cheson, J.M. Bennett, M. Grever et al. // Blood. 1996. -Vol. 87. -P. 4990−7.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphomas. URL: http: Wwww.nccn.org. Accessed March 29, 2009.
- Nogee, L.M. Alterations in SP-B and SP-C expression in neonatal lung disease / L.M. Nogee // Annu. Rev. Physiol. 2004. — Vol. 66. — P. 601−623.
- Non-Hodgkin lymphoma / P. Hartge, S.S. Wang, P.M. Bracci et al. // Cancer Epidemiology and Prevention /ed. by D. Schottenfeld, J.F. Fraumeni Jr. Oxford University Press, New York, 2006. — P. 898−918.
- Non-Hodgkin's lymphoma, leukemia, and exposures in agriculture: results from the Italian multicenter case-control study / L. Miligi, A.S. Costantini, V. Bolejack et al. // Am. J. Industr. Med. 2003. — Vol. 44. -P. 627−636.
- Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation / G. Gahrton, K.H. Robe’rt, K. Friberg et al. // Blood. 1980. — Vol. 56. — P. 640−647.
- NQOl C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China / J.-H. Zhang, Y. Li, R. Wang et al. // World J. Gastroenterol. 2003. — № 9. — P. 1390−3.
- NQOl Polymorphisms and De Novo Childhood Leukemia: A HuGE Review and Meta-Analysis / N. Guha, J.S. Chang, A.P. Chokkalingam et al.//Am. J. Epidemiol.-2008.-Vol. 168.-P. 1221−1232.
- Occupation and risk of non-Hodgkin's lymphoma and chronic lymphocytic leukemia / T. Zheng, A. Blair, Y. Zhang et al. // J. Occup. Environm. Med. 2002. — Vol. 44. — P. 469174.
- Oltari, Z. Bcl-2 heterodimers in vivo with a conserved homolog, Bax, that accelerates programed cell death / Z. Oltari, C. Milliman, S. J. Korsmeyer // Cell. 1993. — Vol. 74. — P. 609−619.
- Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries / O. Landgren, E.A. Engels, N.E. Caporaso et al. // Blood. 2006. — Vol. 108. — P. 292−296.
- Pepper, C. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance / C. Pepper, T. Hoy, D.P. Bentley // Br. J. Cancer. 1997. — Vol. 76. — P. 935−938.
- Pepper, C. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia / C. Pepper, P. Bentley, T. Hoy//Br. J. Haematol. 1996. — Vol. 95.-P. 513−517.
- Personal use of hair dyes and hematolymphopoietic malignancies / L. Miligi, A.S. Costantini, A. Benvenuti et al. // Arch. Environm. Occup. Health. 2005. — Vol. 60. — P. 249−256.
- Pesticide exposures and other agricultural risk factors for leukemia among men in Iowa and Minnesota / L.M. Brown, A. Blair, R. Gibson et al.//Cancer Res. 1990.-Vol. 50.-P. 6585−6591.
- Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2010. — Vol. 51, № 12.- P. 2222−9.
- Pisetsky, D.S. Tumor necrosis factor blockers in rheumatoid arthritis / D.S. Pisetsky // N. Engl. J. Med. 2000. — Vol. 342. — P. 810−811.
- Pittman, S. Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia / S. Pittman, D. Catovsky // Br. J. Haematol.- 1984. Vol. 58. — P. 649−660.
- Polymorphism of the tumour necrosis factoralpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia / J. Demeter, F. Porzsolt, S. Ramisch etal. //Br. J. Haematol. 1997. — Vol. 97.-P. 107−112.
- PRAD-l/Cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma / F. Bosch, P. Jares, E. Campo et al. // Blood. 1994. — Vol. 84. -P. 2726−2732.
- Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL / C. Magnac, R. Porcher, F. Davi et al. // Leukemia. -2003.-Vol. 17.-P. 133−137.
- Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia / M. Adachi, A. Tefferi, P.R. Greipp et al. // J. Exp. Med. 1990. — Vol. 171. — P. 559−564.
- Prevalence of the inactivating 609C—>T polymorphism in the NAD (P)H: quinoneoxidoreductase (NQOl) gene in patients with primaryand therapy-related myeloid leukemia / R.A. Larson, Y. Wang, M. Banerjee et al. // Blood. 1999. — Vol. 94. — P. 803−7.
- Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia / Z.M. Sthoeger et al. // J. Exp. Med. 1989.-Vol. 169.-P. 255−268.
- Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease / R. Foa, M. Massaia, S. Cardona et al. // Blood.- 1990. Vol. 76. — P. 393−400.
- Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia / T. Han, H. Ozer, N. Sadamori et al. // N. Engl. J. Med. 1984. — Vol. 310. — P. 288−292.
- Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia / M. Sarfati, S. Chevret, C. Chastang et al. // Blood.- 1996. Vol. 88. — P. 4259−4264.
- Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia / W.G. Wierda, S. O’Brien, X. Wang et al. // Blood. 2007. — Vol. 109. — P. 4679−4685.
- Prognostic significant of VH mutational status in early stages of CLL / E. Nikitin, E. Stadnik, T. Bialik et al. // Leuk. Lymph. 2003. — Abstr. 129.
- Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities / G. Juliusson, D.G. Oscier, M. Fitchett et al. // N. Engl. J. Med. 1990. — Vol. 323. — P. 720−724.
- Raabe, G.K. Leukemia mortality by cell type in petroleum workers with potential exposure to benzene / G.K. Raabe, O. Wong // Environm. Health Perspect. 1996. -Vol. 104, Suppl. 6.-P. 1381−1392.
- Radiation dose and leukemia risk in patients treated for cancer of the cervix / J.D. Boice Jr. et al. // J. Nat. Cancer Inst. 1987. — Vol. 79. — P. 1295−1311.
- Raffeld, M. bcl-1, t (ll-14), and mantle cell-derived lymphomas / M. Raffeld, E.S. Jaffe//Blood. 1991. — Vol. 78.-P. 259−263.
- Rath, P.C. TNF-induced signaling in apoptosis / P.C. Rath, B.B. Aggarwal // J. Clin. Immunol. 1999. — Vol. 19. — P. 350−364.
- Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale / M.D. Miller, C.F. Paradis, P.R. Plouck et al. // Psychiatr. Res. 1992. — Vol. 41, № 3. -P. 237−48.
- Reed, J.C. Bcl-2 and the regulation of programmed cell death / J.C. Reed//J. Cell Biol. 1994. — Vol. 124, № 1−2.-P. 1−6.
- Reed, J. C: Molecular biology of chronic lymphocytic leukaemia / J.C. Reed // Semin. Oncol. 1998. — Vol. 25. — P. 11−18.
- Register of SGCE Personnel as Means of Evaluation of long-term Effects of Low Doses of ionizing Radiation / R.M. Takhauov, A.B. Karpov,
- M.B. Freidin et al. // The second Asian and Oceanic Congress for Radiation Protection. China, 2006. — P. 351−352.
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori / A.C. Wotherspoon et al. // Lancet. 1993. -№ 342. — P. 575−577.
- Regular use of hair dyes and risk of lymphoma in Spain / Y. Benavente, N. Garcia, E. Domingo-Domenech et al. // Int. J. Epidemiol. -2005.-Vol. 34. -P. 1118−1122.
- Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1 / G. Asher, J. Lotem, B. Cohen et al. // Proc. Natl. Acad. Sei. 2001.-Vol. 98.-P. 1188−93.
- Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia / A. Rosenwald et al. // J. Exp. Med.-2001.-Vol. 194.-P. 1639−1648.
- Relationship of leukemia risk to radiation dose following cancer of the uterine corpus / R.E. Curtis, J.D. Boice Jr., M. Stovall et al. // J. Nat. Cancer Inst. 1994.-Vol. 86.-P. 1315−1324.
- Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia / O. Landgren, J.S. Rapkin, N.E. Caporaso et al. // Blood. 2007. — Vol. 109. — P. 2198−2201.
- Review of the epidemiologic literature on EMF and health / I.C. Ahlbom, E. Cardis, A. Green et al. // Environm. Health Perspect. 2001. -Vol. 109, Suppl. 6. — P. 911−933.
- Role of Bax in the apoptotic response to anticancer agents / L. Zhang, J. Yu, B.H. Park et al. // Science. 2000. — № 290. — P. 989−992.
- Role of NQOl, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia / M. Krajinovic, H. Sinnett, C. Richer et al. // Int. J. Cancer. 2002. — Vol. 97, № 2. — P. 2306.
- Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer / G.I. Perez-Perez, F.J. Bosques-Padilla, M.L. Crosatti et al. // Scand. J. Gastroenterol. 2005. — Vol. 40, № 1. — P. 56−60.
- Rozman, C. Chronic lymphocytic leukemia / C. Rozman, E. Montserrat//NEJM. 1995.-№ 333. — P. 1052−1057.
- Schlesselman, J. Case-control studies. Design, conduct, analysis / J. Schlesselman. -N. Y., Oxford: Oxford University Press, 1982. 96 p.
- Schweitzer, M. Chronic lymphocytic leukaemia in 5 siblings / M. Schweitzer, C.J. Melief, J.E. Ploem // Scand. J. Haematol. 1973. -№ 11.-P. 97−105.
- Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries / J.D. Boice Jr. et al. // J. Nat. Cancer Inst. 1985. — Vol. 74. — P. 955−975.
- Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients / W.G. Finn, N.E. Kay, S.H. Kroft et al. // Am. J. Hematol. 1998. -Vol. 59.-P. 223−229.
- Self-tolerance checkpoints in B-lymphocyte development / C.C. Goodnow et al. // Adv. Immunol. 1995. — Vol. 59. — P. 279−368.
- Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression / C. Matthews, M.A. Catherwood, T.C. Morris et al. // Eur. J. Haematol. 2006. — Vol. 77. — P. 309−317.
- Shaffer, A.L. Lymphoid malignancies: the dark side of b-cell differentiation / A.L. Shaffer, A. Rosenwald, L.M. Staudt // Nature Rev. Immunol. 2000. — Vol. 2, № 12. — P. 920−32.
- Smith, B.J. Iowa radon leukaemia study: a hierarchical population risk model for spatially correlated exposure measured with error / B.J. Smith, L. Zhang, R.W. Field//Statist. Med. 2007. — doi: 10.1002/ sim2884.
- Smith, P.G. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays / P.G. Smith, R. Doll // Br. Med. J. 1982. — Vol. 284. — P. 449−460.
- Smoking and the risk of leukemia, lymphoma, and multiple myeloma (Sweden) / J. Adami, O. Nyren, R. Bergstrom et al. // Cancer Caus. Control. 1998. — № 9. — P. 49−56.
- Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia / W. Reinisch, M. Willheim, M. Hilgarth et al. // J. Clin. Oncol. 1994.-№ 12. — P. 2146−2149.
- Somatically mutated Ig V (Ii)3−21 genes characterize a new subset of chronic lymphocytic leukemia / G. Tobin et al. // Blood. 2002. — Vol. 99. -P. 2262−2264.
- Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia / A.R. Perez-Atayde, S.E. Sallan, U. Tedrow et al.//Am. J. Pathol. 1997. — Vol. 150.-P. 815−821.
- Spontaneous and drug-induced apoptosis is mediated by confirmational changes of Bax and Bak in B-cell chronic lymphocytic leukemia / B. Bellosillo, N. Villamor, A. Lopez-Guillermo et al. // Blood. -2002.-Vol. 100.-P. 1810−1816.
- Student. The probable error of a mean // Biometrika. 1908. — Vol. 6, № l.-P. 1−25.373. t (14−19)/BCL3 rearrangements in lymphoproliferative disorders: A review of 23 cases / L. Michaux et al. // Cancer Gen. Cytogen. 1997. -Vol. 94, Issue 1 — P. 36−43.
- Takkouche, B. Personal use of hair dyes and risk of cancer: a metaanalysis / B. Takkouche, M. Etminan, A. Montes-Martinez // J. Am. Med. Assoc.-2005.-Vol. 293.-P. 2516−2525.
- The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: estimates of radiation-related cancer risks / E. Cardis et al. // Radiat. Res. 2007. — Vol. 167. — P. 396−416.
- The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia / M.A. Kaderi, M. Norberg, F. Murray et al. // Leukemia. 2008. — Vol. 22, № 2. — P. 33 943.
- The clinical significance of tumor necrosis factor-a plasma level in patients having chronic lymphocytic leukemia / A. Ferrajoli, M.J. Keating, T. Manshouri et al.//Blood. 2002. — Vol. 100.-P. 1215−1219.
- The G (-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia / A. Skogsberg, G. Tobin, A. Krober et al. // Leukemia. 2005. — Vol. 20, № 1. — P. 77−81.
- The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants / L.J. Herrinton, M. Goldoft, S.M. Schwartz, N.S. Weiss // Cancer Caus. Control. 1996.-№ 7.-P. 224−230.
- The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin / T. Watanabe, T. Hotta, A. Ichikawa et al.//Blood. 1994.-Vol. 84.-P. 3158−3165.
- The nation-wide Swedish family-cancer database-updated structure and familial rates / K. Hemminki, X. Li, K. Plna et al. // Acta Oncol. -2001.-Vol. 40.-P. 772−777.
- The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression / P. Ghia, G. Guida, S. Stella et al. // Blood. 2002. — Vol. 101, № 4. p. 1262−9.
- The Prognostic Importance of Various 13ql4 Deletions In CLL / S. Malek et al. // ASH Annual Meeting and Exposition. -2010. № III-366.
- The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma / C.S. Zent, W. Ding, S.M. Schwager et al. // Br. J. Haematol. 2008. — Vol. 141, № 5. — P. 615−21.
- The role of the bax gene polymorphism G (-248)A in chronic lymphocytic leukemia / C. Fegan, J. Starczynski, G. Pratt, C. Pepper // Leukemia. 2006. — Vol. 20. — P. 1460−1461.
- The serum p2-microglobulin (|32m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) / M.J. Keating, S. Lerner, H. Kantarjian et al. // Blood. 1995. — Vol. 86, Suppl. l.-P. 606a.
- Therapeutic role of alemtuzumab (Campath-IH) in patients who have failed fludarabine: results of a large international study / M.J. Keating, I. Flinn, V. Jain et al. // Blood. 2002. — Vol. 99. — P. 3554−3561.
- Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation / C. Shustik, R. Mick, R. Silver et al. // Hematol. Oncol. 1988.-№ 3.-P. 7−12.
- Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders / V. Hjalmar, E. Kimby, E. Matutes et al. // Haematologica. 1998. — Vol. 83. — P. 602−609.
- Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients / E. Matutes, D. Oscier, J. Garcia-Marco et al. // Br. J. Haematol. -1996.-Vol. 92. -P. 382−388.
- Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology / T.H. Que, J. Garcia Marco, J. Ellis et al. // Blood. 1993. — Vol. 82. — P. 571−575.
- Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias / A. Criel, I. Wlodarska, P. Meeus et al. // Br. J. Haematol. 1994. — Vol. 87.-P. 523−528.
- Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia / W. Digel, M. Stefanic, W. Schoniger et al. //Blood. 1989.-Vol. 73.-P. 1242−1246.
- Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies / F.T. Cordingley, A. Bianchi, A.V. Hoffbrand et al. //Lancet. 1988,-№ l.-P. 969−971.
- Tumour necrosis factor-a cytokine promoter gene polymorphism in Hodgkin’s disease and chronic lymphocytic leukaemia / W. Christel, J. Sjoberg, M. Intaglietta et al. // Br. J. Haematol. 1999. — Vol. 104. — P. 346−349.
- Tynes, T. Residential and occupational exposure to 50 Hz magnetic fields and hematological cancers in Norway / T. Tynes, T. Haldorsen // Cancer Caus. Control. 2003. — Vol. 14. — P. 715−720.
- Ultraviolet radiation exposure and risk of malignant lymphomas / K.E. Smedby, H. Hjalgrim, M. Melbye et al. // J. Nat. Cancer Instit. 2005. -Vol. 97.-P. 199−209.
- Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia / T.J. Hamblin, Z. Davis, A. Gardiner et al. //Blood. 1999. — Vol. 94. — P. 1848−1854.
- Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia / S.H. Zahm, D.D. Weisenburger, P.A. Babbitt et al. // Am. J. Public Health. 1992. — Vol. 82.-P. 990−997.
- Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale / Y. Conwell, N.T. Forbes, C. Cox, E.D. Caine //J. Am. Geriatr. Soc. 1993. — Vol. 41, № 1. — P. 38−41.
- Validation of the Cumulative Illness Rating Scale in a geriatric residential population / P.A. Parmelee, P.D. Thuras, I.R. Katz, M.P. Lawton // J. Am. Geriatr. Soc. 1995. — Vol. 43, № 2. — P. 130−7.
- Variant translocation of the bcl-2 gene to Ig in a chronic lymphocytic leukemia / M. Adachi, J. Cossmna, D. Longo et al. // Proc. Natl. Acad. Sei. USA. 1989.-Vol. 86.-P. 2771−2774.
- Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration / K. Podar, Y.T. Tai, F.E. Davies et al. // Blood. 2001. — Vol. 98. — P. 428−435.
- Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia / W. Fiedler, U. Graeven, S. Ergun et al. // Blood. 1997. — Vol. 89. — P. 1870−1875.
- VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia / Y.K. Lee, N.D. Bone, A.K. Strege et al. // Blood. 2004. — Vol. 104. — P. 788−794.
- VH3−21 B cells escape from a state of tolerance in rheumatoid arthritis and secrete rheumatoid factor / X. He, J.J. Goronz, W. Zhong et al. // Mol. Med. 1995,-№ i.p. 768−780.
- Videbaek, A. Familial leukemia. A preliminary report / A. Videbaek // Acta Med. Scand. 1947. — Vol. 127. — P. 26−52.
- Vousden, K.H. p53: death star / K.H. Vousden // Cell. 2000. — Vol. 103, № 5. -P. 691−4.
- Waage, A. TNF receptors in chronic lymphocytic leukemia / A. Waage, T. Espevik // Leuk. Lymphoma. 1994. — Vol. 13. — P. 41−46.
- Waldman, E. A prospective evaluation of the cumulative illness rating scale / E. Waldman, J.F. Potter // Aging (Milan, Italy). 1992. — Vol. 4, № 2. — P. 171−8.
- WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer / S.H. Swerdlow et al. Lyon, 2008.
- Wingfield, P. Tumour necrosis factor is a compact trimer / P. Wingfield, R.H. Pain, S. Craig // FEBS Lett. 1987. — Vol. 211. — P. 179 184.
- Zech, L. Chromosome 13 a new marker for B-cell chronic lymphocytic leukemia / L. Zech, H. Mellstedt // Hereditas. — 1988. — Vol. 108.-P. 77−84.